Immuthera Brings Together World’s Top Scientists On New Advisory Board To Advance Cutting-Edge Therapies For Diabetes And Immune Disorders

Immuthera, a leading innovator in cell therapies for autoimmune conditions, and its parent company PolTREG, have announced the first three members of their new Scientific Advisory Board (SAB). These internationally respected experts bring decades of experience and major contributions in the fields of diabetes and immunotherapy.

Their involvement will play a key role in guiding Immuthera’s research and development of next-generation Treg (regulatory T cell) therapies. With the backing of these top scientists, Immuthera aims to deliver safe, effective, and science-driven treatments to patients around the world. 

Prof. Piotr Trzonkowski, CEO of Immuthera and PolTREG, stated, “The collective wisdom and leadership of Drs. Skyler, Schatz, and Steinman provide Immuthera and PolTREG with an unparalleled strategic advantage. Their guidance ensures that our research and clinical programs are aligned with the highest standards of scientific rigor and patient care. Immuthera plans on expanding our SAB over the next several months to build a truly world-class team that will guide our activities in the US and beyond. With their support, Immuthera is uniquely positioned to accelerate the development of transformative therapies for type 1 diabetes and other autoimmune diseases.”

Dr. Desmond Schatz, mentioned, “Regulatory T cells (Treg cells) play a crucial role in maintaining immune homeostasis. As such, Immuthera’s and PolTREG’s delivery of Tregs offers hope for curing or controlling autoimmune diseases, including type 1 diabetes.”

 Dr. Lawrence Steinman also added, "I am excited to provide advice as Immuthera and PolTREG test their exciting technology in the clinic.”

Immuthera is also collaborating with PolTREG and leading academic institutions in the U.S. to build a strong pipeline of clinically validated Treg cell therapies targeting autoimmune and neuroinflammatory diseases.